Soligenix Receives UK Designation for Behçet's Disease Treatment
Soligenix has received Promising Innovative Medicine designation from the UK for its drug SGX945 (dusquetide) for the treatment of Behçet's disease. This designation advances the company's rare disease pipeline.
Topics
Developing
- 865d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 865d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 865d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 865d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Source Alpha
Source Bravo
Source Charlie
Source Delta
Source Echo
Source Foxtrot
Source Golf
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade